Published in Malar J on June 24, 2014
Combating poor-quality anti-malarial medicines: a call to action. Malar J (2016) 1.13
Quality of care for the treatment for uncomplicated malaria in South-East Nigeria: how important is socioeconomic status? Int J Equity Health (2015) 0.80
Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy. Int Health (2016) 0.78
Adherence to treatment guidelines for uncomplicated malaria at two public health facilities in Nigeria; Implications for the 'test and treat' policy of malaria case management. J Pharm Policy Pract (2014) 0.78
Seeking treatment for uncomplicated malaria: experiences from the Kintampo districts of Ghana. Malar J (2016) 0.78
A qualitative study on health workers' and community members' perceived sources, role of information and communication on malaria treatment, prevention and control in southeast Nigeria. BMC Infect Dis (2015) 0.77
Exploring the role of socioeconomic factors in the development and spread of anti-malarial drug resistance: a qualitative study. Malar J (2017) 0.75
Observations on the Prevalence, Characteristics, and Effects of Self-Treatment. Front Public Health (2016) 0.75
Malaria misdiagnosis: effects on the poor and vulnerable. Lancet (2004) 9.15
Improving malaria home treatment by training drug retailers in rural Kenya. Trop Med Int Health (2004) 3.65
Self-treatment for malaria: the evidence and methodological issues. Health Policy Plan (2002) 3.60
Overlap in the clinical features of pneumonia and malaria in African children. Trans R Soc Trop Med Hyg (1994) 3.58
Predictors of the quality of health worker treatment practices for uncomplicated malaria at government health facilities in Kenya. Int J Epidemiol (2004) 3.51
The contribution of microscopy to targeting antimalarial treatment in a low transmission area of Tanzania. Malar J (2006) 3.31
Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities. Trop Med Int Health (2004) 3.22
Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District, Kenya. Malar J (2003) 2.45
Use of over-the-counter malaria medicines in children and adults in three districts in Kenya: implications for private medicine retailer interventions. Malar J (2007) 2.33
Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy. Malar J (2009) 1.85
An in-depth study of patent medicine sellers' perspectives on malaria in a rural Nigerian community. Malar J (2006) 1.85
Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study. Malar J (2007) 1.81
Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets. Malar J (2009) 1.78
Where do people from different socio-economic groups receive diagnosis and treatment for presumptive malaria, in south-eastern Nigeria? Ann Trop Med Parasitol (2005) 1.62
Treatment of uncomplicated malaria at public health facilities and medicine retailers in south-eastern Nigeria. Malar J (2011) 1.58
Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health (2010) 1.38
Malaria treatment perceptions, practices and influences on provider behaviour: comparing hospitals and non-hospitals in south-east Nigeria. Malar J (2009) 1.34
Malaria treatment in the retail sector: knowledge and practices of drug sellers in rural Tanzania. BMC Public Health (2008) 1.31
Examining appropriate diagnosis and treatment of malaria: availability and use of rapid diagnostic tests and artemisinin-based combination therapy in public and private health facilities in south east Nigeria. BMC Public Health (2010) 1.28
Do poor people use poor quality providers? Evidence from the treatment of presumptive malaria in Nigeria. Trop Med Int Health (2011) 1.26
Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries. Malar J (2013) 1.14
Knowledge and behaviour as determinants of anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya. Malar J (2011) 1.07
Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res (1989) 1.03
Anti-malarial prescription practices among outpatients with laboratory-confirmed malaria in the setting of a health facility-based sentinel site surveillance system in Uganda. Malar J (2013) 1.02
The economic burden of malaria on households and the health system in Enugu State southeast Nigeria. PLoS One (2013) 0.84
Effect of pharmaceutical care programme on blood pressure and quality of life in a Nigerian pharmacy. Pharm World Sci (2007) 1.14
First description of Escherichia coli producing CTX-M-15- extended spectrum beta lactamase (ESBL) in out-patients from south eastern Nigeria. Ann Clin Microbiol Antimicrob (2012) 0.97
Aqueous extract of Phyllanthus niruri (Euphorbiaceae) enhances the phenotypic and functional maturation of bone marrow-derived dendritic cells and their antigen-presentation function. Immunopharmacol Immunotoxicol (2010) 0.84
Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase (ESBL) producers isolated from a mixed human population. Bosn J Basic Med Sci (2011) 0.83
Anti-inflammatory and membrane-stabilizing stigmastane steroids from Alchornea floribunda leaves. Planta Med (2009) 0.81
Inhibition of pro-inflammatory cytokines and inducible nitric oxide by extract of Emilia sonchifolia L. aerial parts. Immunopharmacol Immunotoxicol (2012) 0.80
The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC. AIDS Res Ther (2013) 0.80
Activation of murine lymphocytes and modulation of macrophage functions by fractions of Alchornea cordifolia (Euphorbiaceae) leaf extract. Immunopharmacol Immunotoxicol (2010) 0.78
Immunomodulatory and immunorestorative activities of β-D-glucan-rich extract and polysaccharide fraction of mushroom, Pleurutus tuberregium. Pharm Biol (2015) 0.76
The leaf extract of Spondias mombin L. displays an anti-inflammatory effect and suppresses inducible formation of tumor necrosis factor-α and nitric oxide (NO). J Immunotoxicol (2011) 0.76
Effects of Zingiber officinale on the plasma pharmacokinetics and lung penetrations of ciprofloxacin and isoniazid. Am J Ther (2014) 0.75
Extracts of Ficus exasperata leaf inhibit topical and systemic inflammation in rodents and suppress LPS-induced expression of mediators of inflammation in macrophages. J Immunotoxicol (2012) 0.75
Inhibition of inflammatory mediators and reactive oxygen and nitrogen species by some depsidones and diaryl ether derivatives isolated from Corynespora cassiicola, an endophytic fungus of Gongronema latifolium leaves. Immunopharmacol Immunotoxicol (2013) 0.75
Supplementation with aqueous leaf extract of Morinda lucida enhances immunorestoration and upregulates the expression of cytokines and immunostimulatory markers. Immunol Invest (2012) 0.75